Blood 2018 Apr 5
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Related Questions
New comment by Medical Oncologist at Duke University School of Medicine ( December 4, 2020)
What is your opinion on GRAAPH-2005 - lower intensity chemo regimen with TKI had improved outcomes as compared to TKI + hyper cvad?
What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?
New answer by Medical Oncologist at University of Washington (April 2, 2023)
The role of surveillance bone marrow exams in ALL (either B or T-lineage) is a matter of some debate. Thoughtful clinicians can disagree, but in my practice, I do NOT routinel...
For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.&nbs...
New answer by at Emory University (March 5, 2024)
I agree with all of Dr. @Cassaday's answers. We have found it easier than expected to provide blinatumomab for all of the children we feel could benefit from it. Some issues t...